Walgreens Boots Alliance, Inc. (WBA) Q4 2024 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call revealed several negative indicators: a lowered EPS guidance, anticipated pharmacy margin headwinds, and a decline in retail sales. The Q&A highlighted ongoing uncertainties, including a multiyear turnaround plan and unclear timelines for stabilization. Despite some positive elements like net debt reduction and improved gross margins, the overall sentiment remains negative due to the challenging environment and lack of clear guidance, suggesting a potential stock price decline of -2% to -8%.
Key Financial Performance
Adjusted EPS $0.39, decreased 41% year-over-year on a constant-currency basis; decline attributed to lower sale leaseback gains, reversal of incentive accruals in the prior year, and lower Cencora equity income.
GAAP Net Loss $8.6 billion, compared to a loss of $3.1 billion in fiscal '23; included non-cash impairment charges related to VillageMD goodwill and prior year included $5.5 billion after-tax charge for opioid-related claims.
US Retail Pharmacy Comparable Sales 8.3% growth year-on-year; driven by pharmacy sales, partly offset by a decline in retail sales.
US Retail Pharmacy AOI Decreased 60% versus the prior year quarter; decline attributed to lower sale leaseback gains, reversal of incentive accruals, and lower Cencora equity income.
Pharmacy Comp Sales Increased 11.7%, driven by brand inflation and mix impacts; comp scripts excluding immunizations grew 2.6%.
US Retail Comparable Sales Declined 1.7% in the quarter; driven by sales pressure in non-essential categories.
International Total Sales Grew 3.7%, with Germany wholesale increasing 8.2% and Boots UK up 2.3%.
US Healthcare Sales $2.1 billion, increased 7% compared to the prior year quarter; VillageMD sales of $1.5 billion grew 7% year-on-year.
Operating Cash Flow $1 billion for fiscal '24; negatively impacted by $934 million in payments related to legal matters and $386 million in annuity premium contributions.
Free Cash Flow $23 million, declined by $642 million versus the prior year due to lower earnings and higher legal payments; fourth quarter free cash flow of $1.1 billion increased 98% compared to the prior year.
Net Debt Reduction Reduced by nearly $2 billion in fiscal '24; ended the year with $3.2 billion in cash and cash equivalents and $5.8 billion of revolver capacity.
Footprint Optimization Program Expected to close approximately 1,200 stores over the next three years; anticipated benefit of approximately $100 million of AOI in fiscal '25.
Working Capital Initiatives Expected to generate approximately $500 million of free cash flows in fiscal '25.
Capital Expenditure Reductions Expected reductions of approximately $150 million in fiscal '25.
Operating Highlights
New Product Launches: Launched over 300 new owned brand SKUs this year focused in key categories, with expectations to launch another 300-plus in fiscal 2025.
Store Closures: Expect to close approximately 1,200 underperforming stores over the next three years, with about 500 targeted for closure in fiscal 2025.
Footprint Optimization Program: Announced an expanded footprint optimization program to realign store base, focusing on profitable locations.
Cost Reduction: Successfully cut costs by over $1 billion, reduced CapEx by over $700 million, and realized over $600 million in benefits from working capital initiatives.
Cash Flow Improvement: Achieved positive cash flow in the fourth quarter and for the full year, with operating cash flow of $1 billion for fiscal '24.
Strategic Review: Conducted a thorough strategic review to focus on retail pharmacy-led operations, leveraging consumer trust and convenience.
Financial Model: Adopting a disciplined financial model targeting strong free cash flow generation and appropriate leverage.
Risk or Challenges
Cost Reduction: Walgreens Boots Alliance has cut costs by over $1 billion, which is a significant financial risk mitigation strategy.
Store Closures: The company plans to close approximately 1,200 underperforming stores over the next three years, which poses risks related to workforce management and customer retention.
Reimbursement Pressure: There is ongoing pressure on pharmacy reimbursement rates, which could impact profitability and cash flow.
Regulatory Issues: The company is working with regulators to stabilize NADAC (National Average Drug Acquisition Cost) to ensure predictable pharmacy reimbursement.
Economic Factors: The consumer backdrop remains challenging, with price-sensitive shopping behavior affecting retail sales.
Debt Management: Walgreens aims to reduce net debt, having already achieved a $1.9 billion reduction, but ongoing debt management remains a challenge.
Legal Payments: The company anticipates increased legal payments in fiscal 2025, which could impact cash flow.
Market Competition: The company faces competitive pressures from peers who have invested in capabilities that Walgreens is now trying to catch up with.
Supply Chain Challenges: The company is renegotiating supplier contracts to improve cost structures, which presents risks if negotiations do not yield favorable terms.
Healthcare Segment Performance: While the US Healthcare segment is expected to grow, any underperformance could impact overall financial stability.
Guidance & Outlook
Cost Reduction: Successfully cut costs by over $1 billion.
CapEx Reduction: Reduced CapEx by over $700 million.
Working Capital Initiatives: Realized over $600 million in benefits from working capital initiatives.
Store Closures: Expect to close approximately 1,200 underperforming stores over the next three years, with about 500 targeted for fiscal 2025.
Footprint Optimization Program: Announced an expanded footprint optimization program to realign store base and improve cash flow.
Merchandising Strategy: Reevaluating merchandising strategy to offer a refreshed assortment of products, including own brands.
VillageMD Monetization: Plans to monetize VillageMD while redeploying proceeds to reduce net debt.
Pharmacy Margin Stabilization: Focus on stabilizing pharmacy margin and improving reimbursement rates.
Fiscal 2025 Adjusted EPS Guidance: Guidance range of $1.40 to $1.80.
Working Capital Initiatives: Expect to generate approximately $500 million in free cash flows from working capital initiatives.
CapEx Reduction for Fiscal 2025: Expect capital expenditure reductions of approximately $150 million.
US Retail Pharmacy AOI Decline: Expect a year-over-year decline in AOI of $1.1 billion.
International Segment Profitability: Expect profitability growth in the International segment led by Boots retail business in Germany.
US Healthcare Segment EBITDA: Expect adjusted EBITDA for the US Healthcare segment to improve by $250 million in fiscal 2025.
Shareholder Return Plan
Shareholder Return Plan: Walgreens Boots Alliance is focused on improving its balance sheet and cash flow generation. The company plans to monetize non-core assets, including VillageMD, to reduce net debt and improve financial flexibility. The company has reduced its net debt by nearly $2 billion in fiscal 2024 and aims to continue this trend. Additionally, Walgreens is implementing a footprint optimization program, expecting to close approximately 1,200 stores over the next three years, with about 500 targeted for closure in fiscal 2025. This program is anticipated to generate approximately $100 million in adjusted operating income (AOI) in fiscal 2025.
Key Q&A
Earnings Word Cloud
WBA Transcript
The earnings call presents a mixed picture: strong sales growth across segments and improved free cash flow are positive, but the decline in adjusted EPS and operating income, alongside challenges in retail sales, cast a shadow. The Q&A session reveals management's reluctance to provide specific guidance on key metrics, which may concern investors. However, optimistic guidance on reimbursement pressure and healthcare subsegments, along with strategic initiatives like MFCs, balance the sentiment. Given these mixed signals, the stock price is likely to remain neutral over the next two weeks.
The earnings call revealed several negative indicators: a lowered EPS guidance, anticipated pharmacy margin headwinds, and a decline in retail sales. The Q&A highlighted ongoing uncertainties, including a multiyear turnaround plan and unclear timelines for stabilization. Despite some positive elements like net debt reduction and improved gross margins, the overall sentiment remains negative due to the challenging environment and lack of clear guidance, suggesting a potential stock price decline of -2% to -8%.
The earnings call reveals mixed signals: while there are positive aspects like growth in certain segments and strategic initiatives, challenges such as declining free cash flow, gross margin impact, and uncertainties in guidance persist. The Q&A section highlights management's cautious approach due to ongoing industry challenges and lack of specific guidance, which tempers optimism. Overall, the stock is likely to remain stable in the short term.
WBA Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
